AstraZeneca Gains US Priority Review for IMFINZI in MIBC
WILMINGTON, Del. — September 25, 2026 AstraZeneca announced that the US Food and Drug Administration (FDA) has accepted and...
urothelial cancer
Advertisement
Astellas PADCEV and Keytruda Gain Positive CHMP Opinion
Tokyo, Japan, September 17, 2026 Astellas Pharma Inc. has announced that the European Medicines Agency’s Committee for Medicinal Products...
Tyra Reports Phase 2 Dabogratinib Results in Bladder Cancer
San Diego, California, September 10, 2026 Tyra Biosciences, Inc. has reported initial results from the Phase 2 SURF302 clinical...
Context Therapeutics Doses First Patient in CT-202 Phase 1
PHILADELPHIA — September 9, 2026 Context Therapeutics Inc. announced that the first patient has been dosed in the Phase...
Tyra to Present Dabogratinib Phase 2 Bladder Cancer Data
Carlsbad, California, USA, September 4, 2026 Tyra Biosciences, Inc. has announced that it will host a conference call and...
Advertisements
UroGen Submits NDA for UGN-103 Bladder Cancer Treatment
Princeton, New Jersey — August 17, 2026 UroGen Pharma Ltd. announced the submission of a New Drug Application (NDA)...
UroGen Secures U.S. Patent Protection for ZUSDURI Through 2044
PRINCETON, N.J., July 15, 2026 UroGen Pharma announced that the U.S. Patent and Trademark Office (USPTO) has issued a...
Merck Announces Expanded FDA Approval for Keytruda in MIBC
SILVER SPRING, Maryland, July 10, 2026 Merck has received U.S. Food and Drug Administration (FDA) approval for Keytruda® (pembrolizumab)...
UroGen Pharma Expands Oncology Capabilities With New Inducement Grants
PRINCETON, N.J., December 5, 2025 — UroGen Pharma Ltd. has announced the issuance of inducement restricted stock units (RSUs)...
Flare and Merck Partner to Advance FX-909 Combo in Cancer
CAMBRIDGE, MA – October 21, 2025 – Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company pioneering therapies that target...
Advertisement
